<DOC>
	<DOCNO>NCT00315341</DOCNO>
	<brief_summary>The Food Drug Administration ( FDA ) request study compare buprenorphine/naloxone ( BUP/NX ) methadone ( MET ) indices hepatic safety .</brief_summary>
	<brief_title>Starting Treatment With Agonist Replacement Therapies ( START )</brief_title>
	<detailed_description>This randomize , open-label , multi-center , Phase 4 study ass change liver enzymes related treatment buprenorphine/naloxone ( BUP/NX ) methadone ( MET ) participant enter opioid agonist treatment . Randomization stratify , within site , accord normal versus abnormal screening liver function test . Participants meet entry criterion dose 24 week active phase study assessment liver function week 1 , 2 , 4 , 8 , 12 , 16 , 20 , 24 follow-up assessment week 32 . Clinicians encourage treat adequate dos BUP/NX MET .</detailed_description>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>1 . Were age 18 year old , 2 . Met DSMIVTR criterion opioid dependence , 3 . Were good general health , , case medical/psychiatric condition require ongoing treatment , care physician willing continue participant 's medical management cooperate study physician , 4 . For female participant , use one follow acceptable method birth control : 1. oral contraceptive 2. barrier ( diaphragm condom ) spermicide 3 . IUD 4. intrauterine progesterone contraceptive system 5. levonorgestrel implant 6. medroxyprogesterone acetate contraceptive injection 7. contraceptive transdermal patch 8. hormonal vaginal contraceptive ring 9. surgical sterilization 10. complete abstinence sexual intercourse 5 . Able read verbalize understanding study voluntarily sign study inform consent form . 1 . ALT AST value &gt; 5 time upper limit normal per test laboratory range criterion , 2 . ALP value &gt; 3 time upper limit normal per test laboratory criterion , 3 . Any documented past present history ascites , presence esophageal gastric varix , hepatic encephalopathy sign significant liver disease indicate Model Endstage Liver Disease score ( Kamath et al. , 2001 ) ≥11 , 4 . Total bilirubin &gt; 2.0 mg/dl ( participant document Gilbert 's syndrome exclude base criterion ) , 5 . Prothrombin time 3 second prolong , 6 . Albumin level le 2.5 g/dl , 7 . Any cardiopathy risk factor list without evidence normal ECG* report perform within 6 month prior first study medication dose , 1 . Congestive heart failure 2 . Left ventricular hypertrophy 3 . Bradycardia 4 . Hereditary QT prolongation 5 . Uncorrected electrolyte imbalance 6 . Concomitant medication know risk QT interval prolongation ; refer Appendix D list medication . Note : The list allinclusive . *An ECG abnormal one follow occur : Significant ST segment abnormality : ST segment elevation two continuous lead &gt; 0.1 mV ST segment depression great 1 mm flat downsloping 80 msec J point ST segment abnormality identify `` nonspecific '' acceptable . If potential participant 's ECG indicate ST segment elevation depression consistent ischemia , physician obtain medical history cardiac symptom refer participant evaluation . Conduction abnormality : Mobitz II 2nd degree 3rd degree heart block Atrial fibrillation , atrial flutter , nonsinus tachyarrhythmia Three consecutive ectopic ventricular complex rate &gt; 100 per minute . QTc great 450 msec men 480 msec woman Repolarization abnormality : • Acute medical condition would make participation , opinion study physician , medically hazardous ( e.g. , unstable pancreatic , cardiovascular renal disease , significant anemia ) 8 . Known allergy sensitivity BUP , naloxone MET inactive ingredient study medication ( include lactose , mannitol , cornstarch , povidone K30 , citric acid , sodium citrate , FD &amp; C Yellow No.6 color , magnesium stearate , Acesulfame K sweetener ) 9 . Known diagnosis acute psychosis , severe depression imminent suicide risk determine via clinical interview study physician surrogates 10 . DSMIV diagnosis dependence alcohol require immediate medical attention . 11 . DSMIV diagnosis dependence benzodiazepine require immediate medical attention 12 . DSMIV diagnosis dependence depressant , stimulant require immediate medical attention 13 . Participation investigational drug study within past 30 day 14 . Treatment MET , BUP/NX , BUP 15 past 30 day ( illicit use medication allow ) 15 . Pending legal action could prohibit study participation 16 . Unable unwilling comply study requirement 17 . Unable unwilling remain local area duration treatment 18 . Poor venous access venipuncture could accomplish vein extremity eligibility 19 . Pregnant lactating ( female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>